Article

EDUCATED PATIENT CLL Webinar

Author(s):

Join us online for an informative chronic lymphocytic leukemia webinar on Wednesday, June 17, 2020, at 7 - 8 p.m. ET.

Join us online for an informative Chronic Lymphocytic Leukemia webinar including topics highly relevant to patients, caregivers and advocates right now. Participants will have the opportunity to submit questions to be answered live by our expert panel. On this webinar you’ll also hear from the experts on topics such as:

  • Current trends with CLL diagnoses
  • The use of telemedicine
  • Treatment options
  • Mental health and wellness

Register now for access to CURE®’s community of leukemia and lymphoma experts.

https://bit.ly/June17-CLLWebinar

PRESENTING FACULTY

Andre H. Goy, MD

Physician in Chief Hackensack Meridian Health Oncology Care Transformation Service

Chairman & Chief Physician Officer - John Theurer Cancer Center

Lydia Pfund Chair for Lymphoma

Academic Chairman Oncology- Hackensack Meridian School of Medicine at Seton Hall University

Professor of Medicine — Georgetown University

Susan M. O'Brien MD

Professor, Associate Director for Clinical Science

Chao Family Comprehensive Cancer Center at University of California, Irvine

Lori Leslie, MD

Lead for the Indolent lymphoma program in the Lymphoma Division

John Theurer Cancer Center

Andrew Ip, MD

Hematology Attending

John Theurer Cancer Center

Register today! https://bit.ly/June17-CLLWebinar

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Waldenstrom macroglobulinemia is often slow growing, with high survival but lower quality of life over time, explained researcher Alisha Kimble.
Image of woman.
Image of two doctors and text.
Combining JNJ-1900 with Keytruda may improve distant control of lung cancer, explained by Dr. Jared Weiss.
image of serzan.
Dr. Breelyn Wilky explains that personalized treatments are helping improve outcomes for patients with gastrointestinal stromal tumors.
Image of two doctors with text.
Image of doctors with text.
Imiage of two doctors with text.
Treatment with zanzalintinib plus Opdivo and Opdualag is an option worth exploring in patients with previously untreated clear cell renal cell carcinoma
Related Content